Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Adalimumab for Induction and Maintenance of Remission in Moderate to Severe Crohn's Disease
2006-002078-23Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Aug 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in Crohn's disease, sponsored by Abbott Laboratories. Primary endpoint: Safety assessments. Started Aug 2006; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2006-002078-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002078-23.